Physician profile
Eric Jason Okum
NPI 1184737520
$637,000.21
in general payments reported to CMS, 2019-2025
30 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $86K · 2021: $121K · 2022: $171K · 2023: $80K · 2024: $45K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $141K · Travel and Lodging: $14K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $141,250.00 |
| Travel and Lodging | $14,376.15 |
| Food and Beverage | $14,186.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $628,711.61 | 2019-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Edwards Lifesciences Corporation | $1,522.02 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $1,431.50 | 2019-2020 | |
| Legacy Ortho LLC | $1,247.91 | 2025 | |
| Artivion, INC. | $613.13 | 2019-2025 | Amds-Ascyrus Medical |
| Arthrex, INC. | $568.21 | 2025 | |
| Medtronic, INC. | $554.93 | 2021-2024 | Mosaic, Freestyle |
| Abiomed | $363.82 | 2024-2025 | Impella |
| Boston Scientific Corporation | $306.92 | 2019-2025 | General - Tachy, Resonate El Icd Vr, Accolade Sr |
| Hemosonics LLC | $246.38 | 2023 | Quantra Qplus System |
| Haemonetics Corporation | $176.71 | 2023 | Teg6s Hemostasis System |
| Smith+Nephew, INC. | $148.49 | 2024 | Stravix |
| Zimmer Biomet Holdings, INC. | $126.04 | 2025 | |
| Werfen USA LLC | $124.09 | 2023 | |
| Lemaitre Vascular, INC. | $115.74 | 2024-2025 | Artegraft Vascular Graft |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcym INC | $114.83 | 2022 | |
| Abbott Laboratories | $111.41 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Angiodynamics, INC. | $100.50 | 2021 | |
| Ethicon US, LLC | $91.41 | 2024-2025 | Surgiflo Hemostatic Matrix, Vistaseal, Surgicel Nu-Knit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.87 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $53.53 | 2022-2023 | |
| Baxter Healthcare | $52.94 | 2022-2025 | Perclot |
| Astrazeneca Pharmaceuticals Lp | $37.79 | 2021-2022 | |
| Lsi Solutions INC | $28.74 | 2023 | Cor Knot |
| Merck Sharp & Dohme LLC | $18.25 | 2024 | Verquvo |
| Livanova USA, INC. | $18.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.87 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.32 | 2022 | |
| Amgen INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Okum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.